BioRestorative Therapies, Inc.

BRTX

US0906556065

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 21/05/2024 am IST			5-day change	1st Jan Change
1.29 ^USD	-0.77%		-1.53%	-25.86%

15/05	BioRestorative Announces Signing a Five-Year Exclusive Supply Agreement with Cartessa Aesthetics, LLC	CI
08/05	BioRestorative Therapies, Inc. Enhances Preclinical Metabolic Program with A Novel Exosome-Based Biologic Targeting Obesity	CI

Biorestorative Therapies, Inc. Elects Nickolay Kukekov as Director

March 20, 2021 at 02:17 am IST

BioRestorative Therapies, Inc. announced that on March 18, 2021 Nickolay Kukekov was elected a director of the company.

Latest news about BioRestorative Therapies, Inc.

BioRestorative Announces Signing a Five-Year Exclusive Supply Agreement with Cartessa Aesthetics, LLC	15/05	CI
BioRestorative Therapies, Inc. Enhances Preclinical Metabolic Program with A Novel Exosome-Based Biologic Targeting Obesity	08/05	CI
BioRestorative Therapies, Inc. Announces Transformative Commercial Agreement with Cartessa Aesthetics, LLC	30/04	CI
BioRestorative Therapies Shares Rise 17% After FDA Clears Phase 2 Study Protocol Amendment	16/04	DJ
BioRestorative Therapies Says US FDA Clears Amended Protocol for Phase 2 Cell Therapy Trial	16/04	MT
BioRestorative Therapies, Inc. Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment	16/04	CI
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease	08/04	CI
BioRestorative Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04	CI
BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society 2024 Annual Meeting	14/02	CI
Top Midday Decliners	07/02	MT
Top Premarket Decliners	06/02	MT
BioRestorative Therapies Reports Positive Results From Lumbar Disc Treatment Candidate Trial; Shares Rise	05/02	MT
BioRestorative Therapies, Inc. Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease	05/02	CI
BioRestorative Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Sector Update: Health Care Stocks Lower Late Afternoon	19/23/19	MT
Sector Update: Health Care Stocks Mixed Monday Afternoon	18/23/18	MT
Sector Update: Health Care	18/23/18	MT
BioRestorative Therapies Shares Rise After Shareholder Broadrick Dale Boosts Stake	18/23/18	MT
Biorestorative Therapies Enters into Supply Agreement with Evolutionary Biologics	12/23/12	CI
BioRestorative Therapies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	12/23/12	CI
BioRestorative Therapies Secures New York State License to Operate as Tissue Bank	21/23/21	MT
Biorestorative Therapies Inc. Receives License from New York State	21/23/21	CI
BioRestorative Therapies, Inc. announced that it expects to receive $2.07565 million in funding	11/23/11	CI
BioRestorative Therapies Says Lumbar Disc Disease Treatment Recommended to Continue Phase 2 Trial	07/23/07	MT
BioRestorative Therapies, Inc. Receives Unanimous Recommendation to Proceed in Its Phase 2 Clinical Trial for Chronic Lumbar Disc Disease, BRTX-100	07/23/07	CI

Chart BioRestorative Therapies, Inc.

Duration

Period

More charts

BioRestorative Therapies, Inc. is engaged in developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The Company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Ratings for BioRestorative Therapies, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.3 USD

Average target price

10.5 USD

Spread / Average Target

+707.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIORESTORATIVE THERAPIES, INC.	-25.86%	88.01L
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	11TCr
REGENERON PHARMACEUTICALS, INC.	+12.41%	11TCr
ARGENX SE	-2.59%	2.2TCr
BIONTECH SE	-12.38%	2.19TCr
GENMAB A/S	-5.29%	1.92TCr
BEIGENE, LTD.	-3.35%	1.81TCr
WUXI APPTEC CO., LTD.	-38.57%	1.77TCr
NEUROCRINE BIOSCIENCES, INC.	+7.51%	1.43TCr
SAREPTA THERAPEUTICS, INC.	+35.67%	1.24TCr

Bio Therapeutic Drugs